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Abstract 
Objective: 
Recent reports raise concern that children with attention deficit hyperactivity disorder (ADHD) and 
some manic symptoms may worsen with stimulant treatment. This study examines the response to 
methylphenidate in such children. 
Methods: 
Data from children participating in the 1-month methylphenidate titration trial of the Multimodal 
Treatment Study of Children with ADHD were reanalyzed by dividing the sample into children with and 
without some manic symptoms. Two “mania proxies” were constructed using items from the Diagnostic 
Interview Schedule for Children (DISC) or the Child Behavior Checklist (CBCL). Treatment response and 
side effects are compared between participants with and without proxies. 
Results: 
Thirty-two (11%) and 29 (10%) participants fulfilled criteria for the CBCL mania proxy and DISC 
mania proxy, respectively. Presence or absence of either proxy did not predict a greater or lesser response or 
side effects. 
Conclusion: 
Findings suggest that children with ADHD and manic symptoms respond robustly to 
methylphenidate during the first month of treatment and that these children are not more likely to have an 
adverse response to methylphenidate. Further research is needed to explore how such children will respond 
during long-term treatment. Clinicians should not a priori avoid stimulants in children with ADHD and some 
manic symptoms. 
Introduction 
Recent reports document children who have attention deficit hyperactivity disorder 
(ADHD), severe irritability, and mood symptoms but who do not meet all the criteria for bipolar 
disorder (Carlson 1984, 1990, Carlson and Kelly 1998, Wozniak et al. 1995). Investigators 
deliberate about how to characterize, diagnose, and treat these children. Some clinicians claim that 
a child’s poor response to stimulants suggests bipolar disorder. Similarly, clinicians and authors 
cite examples of children who are initially diagnosed with ADHD, have adverse reactions to 
stimulants, and are later diagnosed with bipolar disorder (Papolos and Papolos 1999). There is 
little systematic evidence to support these suppositions. 
Stimulants are proven to be effective in treating ADHD (Connor et al. 2002; Gillberg et al. 
1997; Spencer et al. 1996; Swanson 1993). However, it is unclear if they pose a risk for premature 
development of mania in the subset of children who have manic symptoms in addition to their 
ADHD. Compared to the numerous case reports on mania development with antidepressants, there 
is only one of mania development with stimulant treatment in a child (Koehler-Troy et al. 1986). 
Of the few describing psychotic symptoms in children (Lucas and Weiss 1971; Ney 1967; 
Winsberg et al. 1972), only one of these children had symptoms that may have been symptoms of 
mania, “I felt strong like I could tear everything apart” (Lucas and Weiss 1971). Whether this was 
mania induction or stimulant toxicity is not clear. Additionally, in a chart review of children with 
ADHD receiving stimulants, Cherland and colleagues reported that 9 of 98 children developed 
psychotic symptoms (Cherland and Fitzpatrick 1999). Two of these children were later diagnosed 
with mania. 
DelBello and colleagues conducted a retrospective study of a group of adolescents 
admitted to a psychiatric inpatient unit for mania disorder. They found an association between a 
past history of treatment with stimulants and an earlier onset of bipolar disorder (DelBello et al. 
2001) and suggested that stimulant exposure led to the earlier onset of bipolar disorder. However, 
this was not a prospective study, and it did not control for severity of psychopathology. That is, the 
authors did not address whether these children were more symptomatic at a younger age, leading 
to earlier treatment with stimulants. Carlson and colleagues used a “follow-back” approach to 
examine 6- to 12-year-old boys who had been diagnosed with and treated for “minimal brain 
dysfunction” (Carlson et al. 2000). They found that participants who were diagnosed with mania 
spectrum disorders as young adults responded well to stimulants as children. Moreover, children 
with ADHD and high rates of comorbidity did not develop higher rates of bipolar I disorder than 
children with uncomplicated ADHD as might have been expected if that group had included 
children with mania. Authors have suggested that the high reports of bipolar diagnoses in children 
with ADHD may actually be due to stimulant rebound and not to true bipolar disorder (Sarampote 
et al. 2002). Studies that have examined the effect of stimulants on the mood symptoms in general 
and irritability specifically have generally found improvement rather than exacerbation (Barkley et 
al. 1990; Firestone et al. 1998; Greenhill et al. 2001; Klein et al. 1997; Swanson et al. 1998). 
Similarly, aggression-related behaviors improved in a meta-analysis of children with ADHD 
treated with stimulants (Connor et al. 2002). 
Given the physician’s mandate to “first do no harm,” the question of how to treat children 
with ADHD and manic-like symptoms is important. Should stimulants be avoided completely? 
Should stimulants be prescribed only after prior treatment with mood stabilizers (Biederman et al. 
1999)? If one encounters a child who becomes irritable or decompensates with stimulant 
treatment, are there diagnostic implications? 
We used a large dataset of children with well-characterized ADHD, the Multimodal 
Treatment Study of Children with ADHD (MTA), to answer the following questions: Do children 
with ADHD and some manic symptoms respond differently to stimulants than children with 
ADHD without manic symptoms? Are these children more likely to get taken off stimulants 
because they become more irritable? 
Methods 
This study reports on the participants from the MTA. The recruitment, screening, 
diagnostic instruments, outcome measures, randomization, methods, informed consent, 
institutional board review at the performance sites, and the basic characteristics of the full MTA 
sample have been described previously (Arnold et al. 1997a, 1997b, MTA Cooperative Group 
1999a). Parents participated in the Diagnostic Interview Schedule for Children, Version 2.3 
(DISC; Shaffer et al. 1996), with a 3.0 supplement for disruptive behavior disorders. Participants 
(n = 579) in the original study had ADHD, combined subtype on the DISC, Version 3.0, as 
supplemented with up to two symptoms identified by children’s teachers for cases falling just 
below DISC diagnostic threshold. They were randomized to one of four groups: (a) medication 
management (MedMgt), (b) behavioral treatment (Beh), (c) the combination of MedMgt and Beh 
(Comb), or (d) community comparison. During the first month of treatment, 270 of the 289 
children assigned MedMgt or Comb groups participated in a placebo-controlled, double-blind 
titration. This article addresses the medication and side effects of those participants who were in 
the titration trial. 
Titration procedure 
The titration rationale and procedure has been described previously (Greenhill et al. 1996, 
2001). Briefly, it began with a 4-day, single-blind, safety lead-in period, during which subjects 
were exposed to three progressively higher daily methylphenidate (MPH) doses given three times 
daily. Thereafter, for 28 days, subjects received one of three doses of MPH or placebo in a 
randomized crossover daily-switching, double-blind protocol (five school day repeats of each of 
the four conditions, balanced for day of week and order). 
Measurements 
The measurements of significance to our study are described below. A full description of 
the assessment measurements used in the MTA appears in a previous article (Hinshaw et al. 1997). 
In addition to the DISC, both the participants’ parents (or primary caretakers) and teachers 
completed a Child Behavior Checklist (CBCL; Achenbach 1991a, 1991b). ADHD symptoms were 
measured at baseline with the SNAP (an acronym denoting the names of the instrument’s 
developers), completed by the primary caretaker and the teacher (Swanson 1992). The measure 
generates subscales for inattention, hyperactivity/impulsivity, and oppositional defiant disorder 
(ODD) symptoms. During the titration phase, ADHD symptoms were assessed daily by parents 
and teachers using a 16-item Conners, Loney, and Milich (CLAM) scale, which generates 
Inattentive/Overactive (I/O), Aggressive/Defiant (A/D), and Mixed (I/O+A/D) subscales (Loney 
and Milich 1982; Swanson 1992). Parents and teachers also rated daily the presence and severity 
of 10 adverse events commonly associated with MPH on the Pittsburgh Side Effect Rating Scale 
(Pelham 1993). Only the weekday ratings are included in this study. 
Manic symptoms 
To compare the children with some manic symptoms to the children without manic 
symptoms, we constructed two proxies. These proxies were created to capture the participants who 
had some manic symptoms and do not represent participants who fulfill full criteria for bipolar 
disorder. One proxy was based on the mania section of the DISC. A variable was created using a 
“yes” response to severe irritability and at least one additional mania item (happy/excited, more 
energy than usual, more confident than usual). Specifically, the informant needed to answer yes to 
the irritability lead-in question: “Was there a time when [he/ she] was very irritable, jumpy or edgy 
so that any little thing would upset [him/her] or make [him/her] mad?” and then answer yes to the 
severe irritability question: “Was [he/she] so much more irritable than usual that you or others 
thought that something was wrong with [him/her]?” In addition to answering yes to the severe 
irritability question, the informant had to answer yes to at least one of the following: “In the past 6 
months was there a time when __ seemed much too happy or excited?” “Was there a time when 
[he/she] had a lot more energy than usual, quite different from [his/her] usual self?” or “In the past 
6 months, was there a time when [he/she] seemed very sure of [him/herself] for no good reason, 
like [he/she] could do anything and it would work out?” Hereafter, this construct will be referred to 
as “DISC mania proxy.” The second proxy, hereafter referred to as “CBCL mania proxy,” was 
based on a response pattern on CBCL T scores that several authors have found characterize 
children with bipolar disorder (Biederman et al. 1995; Carlson and Kelly 1998; Dienes et al. 2002; 
Geller et al. 1998; Hazell et al. 1999). Biederman et al. found that severity of T scores 
discriminated children with mania from those with ADHD (Bieder-man et al. 1995). Additionally, 
there appeared to be a characteristic pattern of T scores greater than 70 in the aggressive behavior, 
anxious/ depressed, and attention categories. In that all children in our study by definition had 
inattention problems, the inattention factor was not expected to distinguish those with manic 
symptoms from those without, and its use might confound severity of ADHD with the mania 
proxy. Therefore, our CBCL mania proxy included the children who had T scores greater than 70 
on both the anxious/depressed and aggressive subscales. 
Exclusion criteria and bipolar disorder 
The original intent of the MTA was to study children with ADHD regardless of comorbid 
disorders, with the exception of children who had comorbid bipolar disorder, schizophrenia, or 
autism. In actuality, the exclusion of subjects with bipolar disorder was not implemented. We 
reviewed the exclusion process to determine if children with bipolar disorder had been 
systematically excluded from the MTA sample. The screening process and exclusionary data are 
described in full in a previous article from the MTA (MTA Cooperative Group 1999a). Pertinent to 
our analysis is that neither parent report of bipolar disorder nor DISC diagnosis of mania was 
sufficient for exclusion. The steering committee was not confident in the DISC’s ability to 
generate valid diagnoses of mania, and a research interview such as the Kiddie Schedule for 
Affective Disorders and Schizophrenia in School Age Children was beyond the capacity of the 
MTA. Additionally, we hypothesized that children with bipolar disorder might have taken 
antipsychotic medication in the 6 months prior to screening, an exclusion criteria for the study. We 
reviewed the data from the first two screening assessments, both a convenience sample of 1,614 
phone screens and all of the 1,518 written screens. Of the phone screens reviewed, 4 of 1,614 
participants (0.2%) were taking antipsychotic medication and were excluded from the study, but 
none of the subjects whose parents participated in the written screen had taken antipsychotic 
medication in the past 6 months. In summary, no one was excluded for a bipolar diagnosis; 
however, a few potential participants were excluded for taking antipsychotic medication. 
Statistical analysis 
We compared baseline data of the proxy-positive and proxy-negative groups using a 
two-sample Student’s t test for continuous variables and chi-square tests for nominal data. When 
chi-square was not valid due to cells with low counts, we used Fisher’s exact test. We used random 
effects regression techniques to do the outcome analyses. Response variables were parent and 
teacher versions of the three CLAM subscales (I/O, A/D, I/O+A/D) and parent and teacher 
side-effect ratings. Fixed effects were: site, medication dose (placebo, low, medium, or high), 
mania proxy (either DISC mania proxy or CBCL mania proxy), and Medication Dose x Mania 
Proxy. Random effects were the parameters (intercept and slope) of the regression of the response 
on dose. Finding a Dose x Mania Proxy interaction would provide evidence that children with the 
proxy had a different response than nonproxy children with change in dose. When Medication 
Dose x Mania Proxy was significant, time was added to the model to control for the situation that 
participants might improve over the course of the titration trial, independent of their medication 
dose. This effect was added as a fixed effect. Graphic representations of CLAM responses were 
reviewed. The outcome score at each dose level was estimated based on the regression model 
where CLAM score, proxy, site, and dose are included in the model. For all analyses, because 
previous studies (March et al. 2000, MTA Cooperative Group 1999b) demonstrated that neither 
gender nor ethnicity impacted significantly on results, these two variables were not included as 
covariates. Statistical significance was set at p < 0.05, two-tailed. 
Results 
Baseline data 
Five hundred seventy-nine 7- to 9.9-year-olds were randomized to one of the four 
treatment groups. Of the 289 subjects who were randomized to either MedMgt or Comb, 270 
participated in the titration trial, and they make up our sample. There were 29 (10%) subjects who 
had the DISC mania proxy and 32 (11.1%) subjects who had the CBCL mania proxy. Seven 
participants satisfied criteria for both proxies. The degree of agreement between the proxy 
measures was low (kappa = 0.14) 
Baseline characteristics were compared between proxy-positive and proxy-negative 
groups and are shown in Table 1. For the DISC mania proxy and CBCL mania proxy positive and 
negative groups, there are no significant differences for age, gender, and IQ. The children 
 DISC mania proxy  CBCL mania proxy  
 Positive 
(n=29) 
Negative  Positive Negative  
Variable (n=260) Significancea (n=32) (n=257) Significancea 
Age in years 7.7 7.8 0.09 7.9 7.8 0.40 
Male n (%) 24 (83) 208 (80) 0.72 28 (88) 194 (79) 0.28 
Female n (%) 5 (17) 51 (20) — 4 (13) 51 (21) — 
Ethnicity n (%)       
Caucasian 16 (55) 162 (63) 0.45 20 (63) 155 (64) 0.93 
African American/Black 11 (38) 42 (16) 0.004 5 (16) 42 (17) 0.83 
Non-Black Hispanic 1 (3) 20 (8) 0.71 1 (3) 18 (7) 0.37 
Black Hispanic 1 (3) 4 (2) 0.41 0 4 (2) 1.0 
Asian American/ 
Pacific Islander 
0 1 (0) 1.0 0 1 (0) 1.0 
ADHD = attention deficit hyperactivity disorder; CBCL = Child Behavior Checklist; DISC = 
Diagnostic Interview Schedule for Children; ODD = oppositional defiant disorder symptom subscale; SNAP 
= ADHD symptom rating scale named for developers of the scale; WISC-III = Wechsler Intelligence Scale 
for Children–Third Edition. 
aContinuous characteristics compared with independent t test; nominal data measured using 
chi-square and Fisher ’s exact test. 
Table 1. Baseline Characteristics of the Sample (N = 289) 
in the DISC mania proxy group were more likely to be African American and have a lower 
household income. Children with the proxies were more symptomatic at baseline on a number of 
the ADHD symptoms as measured by the SNAP. Specifically, participants who were positive for 
the DISC proxy scored higher on parent-rated ODD, and participants with the CBCL proxy were 
more symptomatic on parent-rated scores of inattention, hyperactivity/impulsivity, and ODD and 
teacher scores of inattention and hyperactivity/impulsivity. There were no significant differences 
in family history of psychiatric illness by parent report, with the exception of depression, which 
was more frequent in the DISC mania proxy positive group than the DISC mania proxy negative 
group. 
On the DISC, four (1.4%) subjects were diagnosed with mania, three (1.0%) subjects with 
hypomania, and none with cyclothymia or bipolar II. The comorbidities in each proxy group, as 
diagnosed by the DISC, are described in Table 2. 
Interestingly, children with either mania proxy were more likely to have DISC diagnoses 
of generalized anxiety disorder, obsessive-compulsive disorder, major depressive disorder, 
dysthymia, and conduct disorder. In addition, participants with the CBCL mania proxy were also 
more likely to have agoraphobia and any tic disorder (diagnosis of at least one of the following: 
chronic motor tic, chronic vocal tic, transient tic disorder), and those with the DISC mania proxy 
were more likely to have social phobia, bipolar disorder, and conduct disorder. 
Parent and teacher ratings of behavior using the DISC mania proxy 
Table 3 shows the mean ratings on the CLAM outcomes at each dose and also represents 
Mixed 0 27 (10) 0.09 5 (16) 22 (10) 0.22 
Other 0 3 (1) 1.0 1 (3) 2 (1) 0.31 
Household income $20–40000 $30–50000 0.05 $30–50000 $30–50000 0.29 
WISC-III IQ mean       
Verbal 100.8 99.8 0.74 99.5 100.0 0.88 
Performance 101.6 100.7 0.76 98.3 100.9 0.37 
Full Scale 101.1 100.1 0.72 98.7 100.3 0.56 
SNAP parent mean score       
Inattention 2.14 2.06 0.52 2.43 2.02 0.000 
Hyperactive/Impulsive 2.09 1.89 0.11 2.36 1.85 0.000 
ODD 1.92 1.37 0.000 2.27 1.32 0.000 
SNAP teacher mean score       
Inattention 2.13 2.21 0.51 2.32 2.19 0.02 
Hyperactive/Impulsive 2.09 1.96 0.38 2.32 1.92 0.001 
ODD 1.61 1.32 0.11 1.72 1.30 0.26 
Family history n (%)       
ADHD 14 (50) 98 (39) 0.25 15 (47) 93 (39) 0.41 
Alcohol abuse 15 (52) 125 (49) 0.75 17 (53) 122 (50) 0.77 
Drug use 13 (45) 94 (37) 0.39 13 (41) 91 (38) 0.75 
Depression 18 (62) 91(36) 0.006 13 (40) 96 (40) 0.98 
Manic depression 2 (7) 15 (6) 0.69 1 (3) 16 (7) 0.70 
the results from the random regression analyses. For both the parent- and teacher-rated ADHD 
symptoms, the analysis yields significant medication dose effects for all measures, indicating that 
participants were less symptomatic with higher doses of medication. There were no significant 
DISC mania proxy effects or DISC Mania Proxy Medication Dose interactions for all subscales, 
meaning there were no significant differences on CLAM measures between children with and 
without the proxy and that participants with the DISC mania proxy did not have a different degree 
of improvement with increasing dose. 
Parent and teacher behavior ratings using the CBCL mania proxy 
Table 3 also shows the mean ratings for the three symptom subscale scores from the 
CLAM for the participants with and without the CBCL mania proxy and the results from the 
random regression analyses. For the parent- and teacher-rated outcomes of home behavior, the 
analysis yielded significant dose effects on all three measures (I/O, A/D, and I/O+A/D); CBCL 
mania proxy effects on parent-rated A/D, I/O, and I/O+A/D, and teacher-rated A/D. In other 
words, increased dose led to improvement on all subscales, and the CBCL proxy positive 
participants were more impaired on four of six subscales. Additionally, for teacher-rated A/D, 
there was a CBCL Mania Proxy Dose interaction, meaning proxy participants improved more than 
the nonproxy participants as a function of medication dose. However, when time was added to the 
model, this difference was no longer significant. Both parent-rated A/D+I/O and teacher-rated 
A/D are shown graphically in Fig. 1, where the CLAM outcome at each dose level is estimated 
based on the regression model. Note that both are significant for dose, parent-rated A/D+I/O is 
significant for proxy (as demonstrated by the higher scores in the proxy group), and teacher-rated 
A/D is significant for Dose Proxy effects, as illustrated by the different slopes. 
Adverse events related to methylphenidate 
Overall side effects. 
Four subjects were removed during the lead-in period due to prohibitive side effects as 
described by Greenhill and colleagues (Greenhill et al. 2001). One child had buccal movements, 
one had skin picking, another 
 DISC mania proxy, n (%)  CBCL, n (%)  
Diagnosis Positive Negative Significance Positive Negative Significance 
Any anxiety disorder 20 (69) 94 (36) 0.0006 16 (50) 95 (39) 0.22 
Simple phobia 3 (10) 31 (12) 1.0 7 (22) 26 (11) .08 
Social phobia 10 (34) 41 (16) 0.01 5 (16) 45 (18) 0.81 
Panic disorder 0 0 NS 0 0 NS 
Agoraphobia 1 (3) 4 (2) 0.41 3 (9) 2 (1) 0.01 
GAD 7 (24) 13 (5) 0.002 5 (16) 12 (5) 0.03 
OCD 4 (14) 4 (2) 0.004 3 (9) 4 (2) 0.04 
SAD 4 (14) 32 (12) 0.77 6 (19) 29 (12) 0.36 
Any tic disorder 6 (21) 23 (9) 0.05 8 (25) 21 (9) 0.01 
Tourette’s disorder 1 (4) 1 (0) 0.19 0 2 (1) 1.0 
MDD 7 (24) 3 (1) >0.0001 5 (13) 4 (2) 0.001 
Dysthymia 7 (24) 1 (0) >0.0001 3 (9) 4 (2) 0.04 
Mania (bipolar disorder) 2 (7) 2 (1) 0.05 1 (3) 3 (1) 0.39 
Hypomania 1 (3) 2 (1) 0.27 3 (1) 0 1.0 
Bipolar II 0 0 NS 0 0 NS 
Cyclothymia 0 0 NS 0 0 NS 
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F(3, 738) = 4.29, p = 0.005. For the CBCL mania proxy, there were medication dose effects for 
teacher-rated crabbiness (decreasing with increasing dose) and trouble sleeping (increasing with 
increasing dose) and proxy effects of parent-rated worry (participants with proxy were more 
symptomatic). There were no Dose Proxy interactions, meaning that proxy-positive subjects 
respond similarly to proxy-negative subjects with higher doses of medication. 
Discussion 
Summary 
Our main findings are as follows: 
1. In a large sample of children with well-characterized ADHD, parent-DISC-diagnosed bipolar 
disorder is rare (1.4%). However, children with manic symptoms were more common. Ten 
percent of children had the DISC mania proxy, and 11.1% of children had the CBCL mania 
proxy. Children with either mania proxies were more likely to have comorbid illness as 
diagnosed by the DISC. 
2. Children with ADHD with symptoms of mania, not fulfilling full criteria for bipolar disorder, 
responded well to MPH during a 1-month titration trial. Children with the mania proxy 
responded the same on ADHD symptom scales, improving on measures of attention, 
impulsivity, and aggression. 
3. During the titration trial, proxy subjects responded similarly to nonproxy subjects with respect 
to side effects. They did not have more irritability or more adverse effects in response to 
stimulants and were not more likely to discontinue medication due to side effects. However, 
children with DISC mania proxy had a decrease in parent-reported worry compared to those 
without the proxy. 
Limitations 
There are limitations to this study. First, the MTA was not originally designed to examine 
children with ADHD and manic symptoms. It is possible that some potential participants with 
ADHD and manic symptoms were excluded through the screening process because subjects were 
excluded if they had been treated with antipsychotic medication in the last 6 months, were 
currently hospitalized, had missed one fourth of school days in the past 2 months, or were suicidal. 
Second, due to the low number of participants with manic symptoms, the study had limited 
power. This may have altered our capacity to show further differences in treatment and side-effect 
outcomes between the DISC mania proxy positive and negative groups. 
Third, the results from our study may not generalize to other ADHD treatment settings. 
One could argue that the participants, all volunteers, may have been healthier than those seen in 
other tertiary care settings. This, in addition to our exclusion criteria, could explain why our 
sample had less bipolar comorbidity than described by other authors. For example, Biederman and 
colleagues described a sample of children with ADHD drawn from a variety of outpatient settings 
and found that 11% had bipolar disorder (Biederman et al. 1996), compared to the 1.4% of our 
subjects. Alternatively, differences in rates of bipolar disorder might be due to variation in 
assessment, qualifications for caseness, and inclusion of bi-polar variants. It should be noted that 
our patients were referred from a variety of sources including private practitioners, pediatricians, 
advertisements, advocacy groups, and tertiary care referrals, so our findings might be expected to 
approximate what might be found in an outpatient university setting. 
To compare the children from the MTA trial to participants examined by other authors, we 
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similarity between the CBCL mania proxy group and other authors’ bipolar participants is not 
surprising, as this proxy was defined to capture participants with similar CBCL profiles. The 
CBCL mania negative and DISC mania negative participants were similar to the Biederman and 
colleagues ADHD subjects. Additionally, mean T scores were significantly different between the 
proxy-negative and proxy-positive groups in all the scales, with the exception of sex problems in 
the DISC group (data not shown). Interestingly, the MTA participants with manic symptoms had 
similar profiles to those described by Biederman and colleagues and, as our study shows, 
responded as well to stimulants as those without manic symptoms in this 1-month titration trial. 
This lack of adverse effects has also been shown in sicker children who have been admitted to the 
hospital. Carlson and Kelly (1998) compared the response to stimulants in inpatient children with 
ADHD with and without manic symptoms and found that there was a statistically significant yet 
clinically mild improvement in both groups. 
A fourth limitation to our study stems from the lack of valid instruments to assess children 
with ADHD and manic symptoms. More accurate measurement tools and definitions are needed 
for children with comorbid ADHD and bipolar disorder and ADHD with manic symptoms. We are 
unaware of measures that look specifically at children with ADHD and manic symptoms. We 
adapted two instruments to identify children with some manic symptoms. However, the 
instruments had not been validated for these purposes. The degree of agreement between the two 
proxies was remarkably low, suggesting limitations with one or both of these measures. 
Additionally, we analyzed the data using a third proxy that combined the above-mentioned proxies 
using an “or” rule. Our results were similar (data available on request). Researchers are trying to 
create measures that will differentiate children with bipolar disorder from children with ADHD 
(Geller et al. 2002). Similarly, Geller and colleagues have reported acceptable reliability with the 
Washington University in St. Louis Kiddie Schedule for Affective Disorders and Schizophrenia 
(Geller et al. 2001). However, diagnosing mania with structured interviews has been problematic 
even in adults (Kessler 1997). There is a great need for improved and consistent measurement 
tools for children with ADHD and manic symptoms, ADHD and comorbid bipolar disorder, and 
bipolar variants such as bipolar disorder not otherwise specified. 
A fifth limitation is that this study only examines data from the 1-month titration trial. 
Therefore, we are only able to draw conclusions about brief treatment with stimulants, albeit one 
which differs from real-world practice. We did not examine the effects of longer treatments or 
long-term effects. The analysis does not address the concern that children with subsyndromal 
symptoms of bipolar disorder or children with ADHD and manic symptoms might respond well to 
stimulants initially but develop an adverse reaction over time. Similarly, we are not able to predict 
long-term outcome from this 1-month analysis. Our group will later be examining participants’ 
responses at 14 and 24 months. A theoretical sixth limitation is the nature of the titration trial, with 
random daily dose switching and intermittent placebo, different from the usual no-placebo 
escalating clinical titration. This might conceivably make a difference in elicitation or aggravation 
of manic symptoms, though we doubt it. 
Recommendations 
Children with perceived ADHD and manic symptoms need a thorough evaluation to 
establish the presence or absence of ADHD and comorbid diagnoses. Children with ADHD and 
manic symptoms may benefit from a carefully monitored MPH trial. Our study did not look 
specifically at children with ADHD and bipolar disorder. Such studies are still needed. Studies that 
examine the response to stimulants of children with ADHD and manic symptoms over longer 
courses of treatment are needed. Our group intends to examine this in subsequent studies. 
Prospective studies of children with ADHD as adults do not show an increased rate of mood 
disorders (Mannuzza et al. 1998) or Diagnostic and Statistical Manual of Mental Disorders, third 
edition (American Psychiatric Association 1980) diagnoses except antisocial personality disorder 
(Weiss et al. 1985). However, future studies that examine children with ADHD in spite of 
comorbidities, in particular, classic mood disorders using Diagnostic Statistical Manual of Mental 
Disorders, fourth edition (American Psychiatric Association 1994), criteria and bipolar variants, 
are needed. There is a similar need for prospective research examining what long-term risks if any 
may be associated with treatment of stimulants in these populations. 
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